First Episode Psychosis Suspected
Patient presenting with new-onset psychotic symptoms
All Pathways
PsychiatryManagement
First Episode Psychosis Management (APA/VA-DoD)
First Episode Psychosis Management (APA/VA-DoD): First Episode Psychosis Suspected → Comprehensive Assessment → Medical Workup → Identifiable Cause? → T...
Pathway Overview
14 steps
Algorithm Steps
14 total
01Start 02Action Comprehensive Assessment
Evaluate symptoms, history, and function
- Psychotic symptoms: hallucinations, delusions, disorganization
- Duration of symptoms and DUP (duration untreated psychosis)
- Prodromal symptoms history
- Family history of psychosis
- Substance use history (cannabis, stimulants)
- Developmental history
- Baseline functioning and functioning decline
03Action Medical Workup
Rule out organic causes
- CBC, BMP, LFTs, TFTs
- Urine drug screen (comprehensive)
- HIV, syphilis (RPR/VDRL)
- Consider: B12, folate, ANA, anti-NMDAR
- Brain MRI (first episode)
- Consider LP if autoimmune suspected
04Decision Identifiable Cause?
Medical, neurological, or substance-induced?
05Action Treat Underlying Cause
Address primary etiology
- Substance-induced: Abstinence, may resolve
- Medical: Treat underlying condition
- Autoimmune: Immunotherapy
- Re-evaluate psychosis after treatment
06Action Primary Psychotic Disorder
Initiate antipsychotic treatment
07Action Second-Generation Antipsychotic (SGA)
First-line treatment
- Start LOW, go SLOW (FEP very sensitive)
- Aripiprazole: 2-5mg, target 10-15mg
- Risperidone: 0.5-1mg, target 2-4mg
- Olanzapine: 2.5-5mg, target 10-15mg
- Paliperidone: 3mg, target 6mg
- Ziprasidone: 20mg BID, target 60-80mg BID
- Lower doses often effective in FEP
08Action Metabolic Monitoring
Baseline and ongoing
- Weight, BMI, waist circumference
- Fasting glucose and lipid panel
- Blood pressure
- Prolactin if symptomatic
- ECG if using ziprasidone
- Monitor at 4, 8, 12 weeks, then quarterly
09Decision Response at 4-6 Weeks?
Adequate trial at therapeutic dose
10Action Good Response
Continue current treatment
- Continue antipsychotic at effective dose
- Minimum 1-2 years after first episode
- Consider longer if severe episode/poor insight
- Add psychosocial interventions
12Outcome Long-term Management
Recovery-oriented care
- Many FEP patients achieve remission
- Relapse prevention is key
- Monitor for tardive dyskinesia annually
- Address comorbidities (depression, anxiety)
- Support functional recovery
13Action Inadequate Response
Optimize or switch
- Ensure adequate dose and adherence
- Rule out substance use
- Consider switching to different SGA
- After 2 failed SGAs: Clozapine evaluation
- LAI (long-acting injectable) if adherence issue
14Warning Clozapine for Treatment Resistance
Most effective for refractory psychosis
- After 2 adequate SGA trials failed
- REMS enrollment required (US)
- Start 12.5-25mg, titrate slowly
- Target 300-450mg/day, check level
- Weekly ANC monitoring initially
- Most effective antipsychotic
- Path rejoins step 11Shared downstream outcome
Guideline Source
APA Practice Guideline for the Treatment of Patients with Schizophrenia + VA/DoD 2024 Update
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Must rule out medical and substance-induced causes
- Duration of untreated psychosis (DUP) affects prognosis
- Early intervention programs improve outcomes
- Clozapine requires REMS monitoring (ANC)
- Long-term treatment adherence is challenging
Applicable Regions
USEUGlobal
Version 1Next review: 2027-01-11
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Calculator
PHQ-9 (Patient Health Questionnaire-9)
Depression screening and severity assessment
Open page
Compare
AttendMe.ai vs ChatGPT
See how this pathway workflow compares against ChatGPT.
Open page
Commercial
Start free
Run the pathway in a live AttendMe account with citations and tracked usage.
Start free
Related Resources
Frequently Asked Questions
What is the First Episode Psychosis Management (APA/VA-DoD)?
The First Episode Psychosis Management (APA/VA-DoD) is a management clinical algorithm for Psychiatry. It provides a structured decision tree to guide clinical decision-making, based on APA Practice Guideline for the Treatment of Patients with Schizophrenia + VA/DoD 2024 Update.
What guideline is the First Episode Psychosis Management (APA/VA-DoD) based on?
This algorithm is based on APA Practice Guideline for the Treatment of Patients with Schizophrenia + VA/DoD 2024 Update (DOI: 10.1176/appi.books.9780890424841).
What are the limitations of the First Episode Psychosis Management (APA/VA-DoD)?
Known limitations include: Must rule out medical and substance-induced causes; Duration of untreated psychosis (DUP) affects prognosis; Early intervention programs improve outcomes; Clozapine requires REMS monitoring (ANC); Long-term treatment adherence is challenging. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the First Episode Psychosis Management (APA/VA-DoD) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free